This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month’s activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease. But today, a liquid version of one of the most common drugs prescribed to fight breast cancer, tamoxifen, has for the first time become available in the United States under the brand name
Soltamox® (tamoxifen citrate). Soltamox may offer patients who need tamoxifen therapy an important treatment option. Introduced by
DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, Soltamox, a prescription medication, is expected to be available in pharmacies nationwide starting October 22.
Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)
Why liquid tamoxifen?
According to a 2011 study published in
The Lancet, a five-year course of tamoxifen treatment in women with estrogen-receptor-positive breast cancer cut their risk of death by about one-third over a 15-year period. Unfortunately, for some people with breast cancer, the pill form of tamoxifen can be difficult to swallow due to a variety of reasons, including the effects of radiation, surgery and chemotherapy. Some people simply prefer liquid medications over pills or hope to reduce the number of pills they need to take on a daily basis.
Liquid medications may be appropriate for people who have difficulty or discomfort swallowing solid content. People who have trouble swallowing pills may miss doses of prescribed medications or discontinue them entirely. “Treatment of breast cancer with tamoxifen is a long-term commitment for patients if they are to have the best chance of preventing the disease from recurring,” said oncologist Jivesh Sharma, MD, clinical faculty member at Presbyterian Hospital in Dallas, Texas. “A liquid version of tamoxifen may help people with breast cancer stay on their tamoxifen therapy.”